Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Acalabrutinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 24,515Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Bioinvent Presents Ph 2a Data For BI-1206 Combo In r/r NHL
    Bioinvent Presents Ph 2a Data For BI-1206 Combo In r/r NHL

    03 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-03/bioinvent-to-present-early-phase-2a-data-from-ongoing-trial-with-triple-combination-of-bi-1206-ritu

    PHARMIWEB
    03 Nov 2025
    Share Share
    Abbvie Submitted sNDA for Venetoclax in Untreated CLL
    Abbvie Submitted sNDA for Venetoclax in Untreated CLL

    30 Jul 2025

    // PRESS RELEASE

    https://news.abbvie.com/2025-07-29-AbbVie-Submits-for-U-S-FDA-Approval-of-Combination-Treatment-of-VENCLEXTA-R-venetoclax-and-Acalabrutinib-for-Previously-Untreated-Patients-with-Chronic-Lymphocytic-Leukemia-CLL

    PRESS RELEASE
    30 Jul 2025
    Share Share
    EU Approves Calquence-Based Regimens for CLL Patients
    EU Approves Calquence-Based Regimens for CLL Patients

    07 Jun 2025

    // PRESS RELEASE

    https://www.astrazeneca.com/media-centre/press-releases/2025/fixed-duration-calquence-approved-in-eu-for-1l-cll.html

    PRESS RELEASE
    07 Jun 2025
    Share Share
    FDA Approves Acalabrutinib for Mantle Cell Lymphoma
    FDA Approves Acalabrutinib for Mantle Cell Lymphoma

    17 Jan 2025

    // PRESS RELEASE

    https://www.astrazeneca.com/media-centre/press-releases/2025/calquence-combination-approved-in-us-for-1l-mcl.html

    PRESS RELEASE
    17 Jan 2025
    Share Share
    CALQUENCE® Gets US Priority Review For Mantle Cell Lymphoma
    CALQUENCE® Gets US Priority Review For Mantle Cell Lymphoma

    03 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241003958806/en

    BUSINESSWIRE
    03 Oct 2024
    Share Share
    AstraZeneca trumpets new Calquence combos in chronic lymphocytic leukaemia
    AstraZeneca trumpets new Calquence combos in chronic lymphocytic leukaemia

    30 Jul 2024

    // PRESS RELEASE

    https://www.astrazeneca.com/media-centre/press-releases/2024/calquence-fixed-duration-combo-improved-1l-cll-pfs.html

    PRESS RELEASE
    30 Jul 2024
    Share Share